EV Biologics Corp. announced that it has signed an exclusive multi-year agreement with INNOVARE for distribution in South America. This agreement will facilitate the launch, in South America and the Caribbean, of EV Biologics regenerative health products, which are currently in production by its wholly owned subsidiary, EXCYTE.

INNOVARE has long standing relationships and agreements in place with established medical product companies, which have direct distribution channels throughout South America and the Caribbean. With Joint Ventures already in place, this agreement will provide direct contact with over 11,000 top private-practice physicians and surgeons representing all the medical specialties. INNOVARE will also conduct extensive training modules on these regenerative health products and how they may address patients' multifaceted and multifactorial health issues and support cardiovascular, dermatologic, neurologic, and musculoskeletal health and longevity.

The company will be seeking agents and sole agents in Asian countries for distribution as well. As announced on February,17, 2023, the company successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. The company plan to utilize these cell banks for production.